2026-01-29 - Analysis Report
**Company Overview**
Abbott Labs is a multinational healthcare and medical device company.

**Return Rate Comparison**
Cumulative return of review stock (ABT): **55.09%**
Cumulative return of comparison stock (S&P 500, VOO): **128.51%**
Divergence (last day): **-73.40**

The cumulative return of Abbott Labs (ABT) is lower than the S&P 500 (VOO) index by 73.40%.

**Alpha, Beta Analysis**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 54.0% | 11.7% | 45.0% | 1.1 | 123.3B |
| 2017-2019  | 64.0% | 11.7% | 39.0% | 1.0 | 148.1B |
| 2018-2020  | 51.0% | 29.7% | 27.0% | 0.9 | 186.7B |
| 2019-2021  | 76.0% | 29.7% | 12.0% | 0.8 | 239.9B |
| 2020-2022  | 0.0% | 28.9% | -4.0% | 0.8 | 187.2B |
| 2021-2023  | -56.0% | 26.1% | -74.0% | 0.7 | 187.7B |
| 2022-2024  | -43.0% | 21.3% | -72.0% | 0.7 | 192.8B |
| 2023-2025  | 7.0% | 19.0% | -69.0% | 0.3 | 213.6B |

Overall, the return on investment (ROI) ranges from negative 56% to a gain of 76%.

**Recent Stock Price Fluctuations**
|  | Value |
| --- | --- |
| Close | $108.27 |
| Last-market | $106.05 |
| 5-day SMA | $110.76 |
| 20-day SMA | $121.37 |
| 60-day SMA | $124.51 |

The current stock price ($106.05) is slightly below the 5-day moving average ($110.76) and below the 20-day moving average ($121.37).

**RSI, PPO Index Indicators**
|  | Value |
| --- | --- |
| Market Risk Indicator (MRI) | 0.70 |
| RSI | 8.68 |
| PPO | -1.61 |
| Hybrid Signal | Buy (Cash 0%) |
| Risk Level | Medium |
| Recent (20 days) relative divergence change | -3.00 |
| 7-day Rank change | 13 |
| 7-day Dynamic Expected Return change | 865.90 |

The market risk indicator (MRI) is 0.70, indicating a medium risk level. The RSI is 8.68, suggesting over-sold conditions. The PPO is -1.61, indicating a sell signal.

**Expected Return**
-734.90%

**Recent News & Significant Events**
[2026-01-28] Abbott Stock Fell the Most in 23 Years After Earnings. The CEO Bought $2 Million of Shares. - Barron's (news.google.com)
[2026-01-28] Hereâ€™s Why Abbott Stock Could Deliver 10% Upside in 2026 After 15% Decline Last Year - TIKR.com (news.google.com)
[2026-01-28] Abbott Laboratories Stock Now 19% Cheaper, Time To Buy - Trefis (news.google.com)
[2026-01-22] Why Abbott Laboratories (ABT) Shares Are Sliding Today - Yahoo Finance (news.google.com)
[2026-01-22] Abbott Tumbles On Disappointing Fourth Quarter As Exact Closing Looms - Investor's Business Daily (news.google.com)
[2026-01-23] Is The Fall In Abbott Stock Justified? - Forbes (news.google.com)

**Analyst Opinions**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.79 (~Buy)
- Opinions: 24
- Target Price (avg/high/low): 136.32 / 169.00 / 115.00

**Recent Earnings Analysis**
| Date | EPS | Revenue |
| ---:|---:|:----:|
| 2025-10-29 | 0.94 | 11.37 B$ |
| 2025-07-30 | 1.02 | 11.14 B$ |
| 2025-04-30 | 0.76 | 10.36 B$ |
| 2024-10-31 | 0.94 | 10.63 B$ |
| 2025-10-29 | 0.94 | 10.63 B$ |

EPS has been relatively stable, with revenue showing slight growth.

**Financial Information = 5. Revenue and Profitability**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.37B | 55.36% |
| 2025-06-30 | $11.14B | 56.44% |
| 2025-03-31 | $10.36B | 56.86% |
| 2024-12-31 | $10.97B | 54.97% |

Revenue has been relatively stable, with profit margins fluctuating between 54.97% and 56.86%.

**Financial Information = 6. Capital and Profitability**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $50.95B | 3.23% |
| 2025-06-30 | $50.56B | 3.52% |
| 2025-03-31 | $48.81B | 2.71% |
| 2024-12-31 | $47.66B | 19.36% |

Equity has been stable, with ROE fluctuating significantly.

**Comprehensive Analysis**
The cumulative return of Abbott Labs (ABT) is lower than the S&P 500 (VOO) index by 73.40%. The 5-day moving average is $110.76, and the stock price is $106.05. The market risk indicator (MRI) is 0.70, indicating a medium risk level. The RSI is 8.68, suggesting over-sold conditions. The PPO is -1.61, indicating a sell signal. The expected return is -734.90%. EPS has been relatively stable, with revenue showing slight growth. Profit margins and equity have also fluctuated.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.